Xceleron has pioneered the use of AMS analysis in pre-clinical and clinical development. AMS is the world's most sensitive analytical instrument and can provide critical human metabolism data at an early stage in the development process. The bulk of the operations are now run out of Maryland, US. Xceleron was sold to Pharmaron in January 2017.